A prospective study reported that longitudinal increases in circulating Granzyme B and activated cytotoxic lymphocytes track response and survival in patients receiving second-line nivolumab for advanced non-small cell lung cancer. The analysis supports the idea that dynamic immune activation markers may better reflect on-treatment biology than single time-point measurements. If validated in larger cohorts, Granzyme B trajectory could support patient monitoring approaches and potentially refine selection strategies for checkpoint inhibitor continuation or combination regimens. For biotech teams, the practical value is in designing translational plans that prospectively pre-specify how immune markers will map to clinical endpoints, especially in post-progression settings.